0001127602-22-006314.txt : 20220223 0001127602-22-006314.hdr.sgml : 20220223 20220223163420 ACCESSION NUMBER: 0001127602-22-006314 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220218 FILED AS OF DATE: 20220223 DATE AS OF CHANGE: 20220223 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McCubbin Quentin CENTRAL INDEX KEY: 0001842009 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39062 FILM NUMBER: 22664355 MAIL ADDRESS: STREET 1: C/O FREQUENCY THERAPEUTICS, INC. STREET 2: 10 PRESIDENTIAL WAY, 2ND FLOOR CITY: WOBURN STATE: MA ZIP: 01801 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Frequency Therapeutics, Inc. CENTRAL INDEX KEY: 0001703647 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 472324450 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 75 HAYDEN AVENUE STREET 2: SUITE 300 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-315-4600 MAIL ADDRESS: STREET 1: 75 HAYDEN AVENUE STREET 2: SUITE 300 CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2022-02-18 0001703647 Frequency Therapeutics, Inc. FREQ 0001842009 McCubbin Quentin 75 HAYDEN AVE SUITE 300 LEXINGTON MA 02421 1 Chief Manufacturing Officer Common Stock 2022-02-18 4 S 0 1411 3.872 D 24355 D Common Stock 2022-02-22 4 S 0 1584 3.534 D 22771 D Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units and does not represent discretionary trades by the Reporting Person. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $3.80 to $3.95. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $3.40 to $3.73. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. /s/ James P. Abely, Attorney-in-Fact for Quentin McCubbin 2022-02-23